- Went public, Oct 2003
- Raised $7.5M PIPE, Jul 2023
- Raised $10M PIPE, Mar 2020
About
BrainStorm Cell Therapeutics is pioneering the field of neurodegenerative disease treatment with a strong focus on amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). At the heart of BrainStorm's innovative approach is NurOwn®, a breakthrough technology that transforms autologous mesenchymal stem cells into neurotrophic factor-secreting cells. This unique process is designed to deliver critical growth factors directly to areas affected by neurodegenerative conditions, offering new hope for patients with ALS and MS.
Recent strategic developments at BrainStorm highlight the company's commitment to overcoming the challenges of neurodegenerative diseases. Through ongoing engagement with regulatory authorities, BrainStorm is dedicated to advancing NurOwn® and ensuring it meets the rigorous standards for efficacy and safety. The company's proactive and collaborative approach with regulatory bodies underscores its dedication to bringing NurOwn® to patients in need.
In response to the evolving landscape of therapeutic development, BrainStorm has undertaken a strategic realignment to accelerate the development of NurOwn® for both ALS and MS. This includes streamlining operations and focusing resources on critical aspects of clinical trials and regulatory submissions, ensuring that BrainStorm remains at the forefront of innovation in treating neurodegenerative diseases.
For the latest information on BrainStorm's efforts and developments in ALS and MS treatment, please visit the BrainStorm [website](https://www.ir.brainstorm-cell.com) or review detailed articles from reputable news sources that cover these significant advancements.
Funding history · 16 rounds · $67.1M total
Q&A
- What is BrainStorm's primary focus in therapeutic development?
- BrainStorm Cell Therapeutics primarily focuses on developing autologous stem cell therapeutics for neurodegenerative disorders, specifically amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), using its NurOwn® technology.
- When did BrainStorm go public?
- BrainStorm went public on NASDAQ in October 2003.
- What was BrainStorm's most recent funding round?
- BrainStorm secured a PIPE funding round in May 2026, raising $400,000.
- How many employees does BrainStorm currently have?
- BrainStorm has an employee count in the 11-50 range.
- What is NurOwn®?
- NurOwn® is BrainStorm's breakthrough technology that transforms autologous mesenchymal stem cells into neurotrophic factor-secreting cells, designed to deliver critical growth factors to areas affected by neurodegenerative conditions.
- Where is BrainStorm's headquarters located?
- BrainStorm's headquarters is located in Petah Tikva, Israel.
- What was BrainStorm's total funding raised to date?
- BrainStorm has raised a total of $67,128,019 USD in funding.
- Which organization provided a grant to BrainStorm in April 2020?
- The Israel Innovation Authority provided a grant of $1,500,000 to BrainStorm in April 2020.
- Who is the President & CEO of BrainStorm?
- Chaim Lebovits serves as the President & CEO of BrainStorm.
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | brainstorm-cell.com |
|---|---|
| linkedin.com/company/2665125 | |
| facebook.com/BrainStormCell |
Identifiers & details
| Founded | 2000-1 |
|---|---|
| Employees (exact) | 32 |
| Offices | New York |
| Market cap | $6.1M |
| Status reason | Public on NASDAQ on Oct 2003; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2003-10 |